Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

Triple negative breast cancer: new therapeutic approaches and BRCA status

(2018) Gamze Guney Eskiler et al.   APMIS

Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer

(2018) Gamze Guney Eskiler et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

PARP inhibitors: Clinical utility and possibilities of overcoming resistance

(2017) Benjamin G. Bitler et al.   GYNECOLOGIC ONCOLOGY

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

(2016) Ruoxi Hong et al.   BMC CANCER

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

PARP inhibitors in the management of breast cancer: current data and future prospects

(2015) Luca Livraghi et al.   BMC Medicine

Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent

(2015) Bing Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

NF-kB signaling mediates acquired resistance after PARP inhibition

(2015) Yuko Nakagawa et al.   Oncotarget

New Strategies for Triple-Negative Breast Cancer--Deciphering the Heterogeneity

(2014) I. A. Mayer et al.   CLINICAL CANCER RESEARCH

Preparation and characterization of ascorbic acid loaded solid lipid nanoparticles and investigation of their apoptotic effects

(2014) Gamze Güney et al.   COLLOIDS AND SURFACES B-BIOINTERFACES

Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro

(2014) Romana Koppensteiner et al.   PLoS One

miRNA Dysregulation in Breast Cancer

(2013) L. Mulrane et al.   CANCER RESEARCH

Genetic Susceptibility to Triple-Negative Breast Cancer

(2013) K. N. Stevens et al.   CANCER RESEARCH

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition

(2013) Maria Gilardini Montani et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Mechanisms of resistance to therapies targeting BRCA-mutant cancers

(2013) Christopher J Lord et al.   NATURE MEDICINE

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer

(2013) S Postel-Vinay et al.   ONCOGENE

Mechanisms of Resistance to PARP Inhibitors—Three and Counting

(2013) Tito Fojo et al.   Cancer Discovery

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

miRNA response to DNA damage

(2011) Guohui Wan et al.   TRENDS IN BIOCHEMICAL SCIENCES

Morphologic transformation of human breast epithelial cells MCF-10A: dependence on an oxidative microenvironment and estrogen/epidermal growth factor receptors

(2010) Rita Yusuf et al.   Cancer Cell International

Role of microRNA in anticancer drug resistance

(2009) Tongsen Zheng et al.   INTERNATIONAL JOURNAL OF CANCER

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY